
Methyl 6-amino-9-β-D-ribofuranosyl-9H-purine-2-carboxylate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
